MA26692A1 - Compositions pharmaceutiques contenant un complexe stable insoluble, procede de preparation et complexe stable insoluble obtenu - Google Patents

Compositions pharmaceutiques contenant un complexe stable insoluble, procede de preparation et complexe stable insoluble obtenu

Info

Publication number
MA26692A1
MA26692A1 MA25778A MA25778A MA26692A1 MA 26692 A1 MA26692 A1 MA 26692A1 MA 25778 A MA25778 A MA 25778A MA 25778 A MA25778 A MA 25778A MA 26692 A1 MA26692 A1 MA 26692A1
Authority
MA
Morocco
Prior art keywords
stable complex
insoluble
insoluble stable
preparation
pharmaceutical compositions
Prior art date
Application number
MA25778A
Other languages
English (en)
French (fr)
Inventor
Phuapradit Wantanee
K Sandhu Harpreet
A Albano Antonio
Hargovindas Shah Navnit
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26798138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA26692(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26692A1 publication Critical patent/MA26692A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA25778A 1998-09-22 1999-09-21 Compositions pharmaceutiques contenant un complexe stable insoluble, procede de preparation et complexe stable insoluble obtenu MA26692A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10133698P 1998-09-22 1998-09-22
US13653199P 1999-05-28 1999-05-28

Publications (1)

Publication Number Publication Date
MA26692A1 true MA26692A1 (fr) 2004-12-20

Family

ID=26798138

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25778A MA26692A1 (fr) 1998-09-22 1999-09-21 Compositions pharmaceutiques contenant un complexe stable insoluble, procede de preparation et complexe stable insoluble obtenu

Country Status (32)

Country Link
US (1) US6350786B1 (Direct)
EP (1) EP0988863B2 (Direct)
JP (5) JP2000095708A (Direct)
KR (1) KR100362019B1 (Direct)
CN (1) CN1201821C (Direct)
AR (2) AR022096A1 (Direct)
AT (1) ATE265232T1 (Direct)
AU (1) AU770745B2 (Direct)
BR (1) BR9904283A (Direct)
CA (1) CA2282906C (Direct)
CO (1) CO5140077A1 (Direct)
CZ (1) CZ300215B6 (Direct)
DE (1) DE69916733T3 (Direct)
DK (1) DK0988863T4 (Direct)
ES (1) ES2218918T5 (Direct)
HR (1) HRP990287B1 (Direct)
HU (1) HU228341B1 (Direct)
ID (1) ID24034A (Direct)
IL (1) IL131957A (Direct)
MA (1) MA26692A1 (Direct)
MY (1) MY124377A (Direct)
NO (1) NO326928B1 (Direct)
NZ (1) NZ337884A (Direct)
PE (1) PE20001049A1 (Direct)
PL (1) PL202757B1 (Direct)
PT (1) PT988863E (Direct)
RS (1) RS50193B (Direct)
RU (1) RU2240827C2 (Direct)
SG (1) SG97131A1 (Direct)
SI (1) SI0988863T2 (Direct)
TR (1) TR199902324A3 (Direct)
TW (1) TWI234465B (Direct)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2307482T3 (es) 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
US6440959B1 (en) * 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
AR033651A1 (es) * 1999-10-01 2004-01-07 Hoffmann La Roche Derivados de pirimidina-2,4,6-triona, composiciones farmaceuticas que contienen dichos compuestos y el empleo de los mismos para la manufactura de un medicamento
US6313143B1 (en) * 1999-12-16 2001-11-06 Hoffmann-La Roche Inc. Substituted pyrroles
MXPA02011427A (es) * 2000-05-16 2004-09-10 Johnson & Johnson Procedimiento para revestir dispositivos medicos utilizando dioxido de carbono supercritico.
US6469179B1 (en) 2000-10-03 2002-10-22 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
US6482847B2 (en) 2000-10-03 2002-11-19 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6869617B2 (en) 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6548531B2 (en) 2001-02-09 2003-04-15 Hoffmann-La Roche Inc. Method for cancer therapy
US6716845B2 (en) * 2001-03-30 2004-04-06 Hoffmann-La Roche Inc. Barbituric acid derivatives
WO2003013478A2 (en) * 2001-05-30 2003-02-20 Csir Method of encapsulating an active substance
US20030044514A1 (en) * 2001-06-13 2003-03-06 Richard Robert E. Using supercritical fluids to infuse therapeutic on a medical device
WO2002102373A1 (en) * 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag Method for administration of cancer therapeutic
BR0210518A (pt) 2001-06-22 2004-06-22 Pfizer Prod Inc Composições farmacêuticas de dispersões de drogas e polìmeros neutros
TNSN03137A1 (en) 2001-06-22 2005-12-23 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS COMPRISING LOW SOLUBILITY AND / OR ACID SENSITIVE DRUGS AND NEUTRALIZED ACID POLYMERS.
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
JP2005504090A (ja) 2001-09-26 2005-02-10 バクスター・インターナショナル・インコーポレイテッド 分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US20030139373A1 (en) * 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
EP1469833B1 (en) 2002-02-01 2021-05-19 Bend Research, Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
MXPA05000977A (es) 2002-08-12 2005-05-16 Pfizer Prod Inc Composiciones farmaceuticas de farmacos semiordenados y polimeros.
DE10351087A1 (de) * 2003-10-31 2005-05-25 Bayer Technology Services Gmbh Feste Wirkstoff-Formulierung
JP4947482B2 (ja) * 2003-11-14 2012-06-06 味の素株式会社 フェニルアラニン誘導体の徐放性経口投与製剤
PL1683524T3 (pl) 2003-11-14 2011-06-30 Ea Pharma Co Ltd Stała dyspersja lub preparat farmaceutyczny stałej dyspersji pochodnej fenyloalaniny
RU2411043C2 (ru) * 2004-04-01 2011-02-10 Юниверсите Де Льеж Фармацевтические композиции пиримидин-2,4,6-трионов
AR049915A1 (es) * 2004-06-14 2006-09-13 Anacor Pharmaceuticals Inc Compuestos con contenido de boro y metodos de uso de los mismos
WO2006062980A2 (en) * 2004-12-07 2006-06-15 Nektar Therapeutics Stable non-crystalline formulation comprising tiagabine
CN101115469A (zh) * 2004-12-28 2008-01-30 卫材R&D管理有限公司 速崩片及其制造方法
DK1848430T3 (da) * 2004-12-31 2017-11-06 Dr Reddys Laboratories Ltd Nye benzylamin-derivativer som cetp-inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
TW200633723A (en) * 2005-01-27 2006-10-01 Corium Int Inc Hydrophilic biocompatible adhesive formulations and uses
EP1690528A1 (de) * 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
WO2006123223A1 (en) * 2005-05-19 2006-11-23 Pfizer Inc. Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
EP1767194A1 (de) * 2005-06-09 2007-03-28 Helm AG Verfahren zur Herstellung von Adsorbaten des Drospirenons
UA95244C2 (ru) * 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
US20080031944A1 (en) * 2006-08-04 2008-02-07 Cima Labs Inc. Stabilization of lorazepam
TW200815033A (en) * 2006-08-10 2008-04-01 Cipla Ltd Antiretroviral solid oral composition
US20080107725A1 (en) * 2006-10-13 2008-05-08 Albano Antonio A Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008079909A1 (en) * 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
PE20081581A1 (es) * 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
WO2008081829A1 (ja) 2006-12-27 2008-07-10 Astellas Pharma Inc. 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ
EP2155166A2 (en) * 2007-05-11 2010-02-24 F. Hoffmann-Roche AG Pharmaceutical compositions for poorly soluble drugs
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
EP1997479A1 (en) * 2007-05-31 2008-12-03 Helm AG Stabilized amorphous candesartan cilexetil compositions for oral administration
BRPI0814423B1 (pt) 2007-07-17 2022-04-19 Plexxikon, Inc Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos
AU2008312321A1 (en) * 2007-10-19 2009-04-23 Purdue Research Foundation Solid formulations of crystalline compounds
US8632805B2 (en) * 2008-06-20 2014-01-21 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
US7794750B2 (en) * 2008-06-20 2010-09-14 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
US20100099696A1 (en) * 2008-10-16 2010-04-22 Anthony Edward Soscia Tamper resistant oral dosage forms containing an embolizing agent
KR20100073454A (ko) * 2008-12-23 2010-07-01 국립암센터 트란스글루타미나제 억제제로 사용되는 신규한 피라졸로디아제핀계 화합물, 이의 제조방법 및 이를 포함하는 조성물
MY160737A (en) * 2009-04-03 2017-03-15 Hoffmann La Roche Propane-i-sulfonic acid {3- [5-(4-chloro-phenyl) -1h -pyrrolo [2, 3-b] pyridine-3-carbonyl] -2,4 difluoro-phenyl} - amide compositions and uses thereof
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
JP2013510166A (ja) 2009-11-06 2013-03-21 プレキシコン インコーポレーテッド キナーゼ調節のための化合物、方法およびその適用
WO2011152297A1 (ja) * 2010-05-31 2011-12-08 アステラス製薬株式会社 トリアゾール化合物の固体分散体
US9624213B2 (en) 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
MX2013008476A (es) 2011-02-17 2013-08-12 Hoffmann La Roche Proceso para cristalizacion controlada de un ingrediente farmaceutico activo a partir del estado liquido superenfriado por extrusion de fusion en caliente.
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
CA2837820C (en) 2011-06-20 2019-02-19 H. Lundbeck A/S Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
JP5964965B2 (ja) 2011-08-18 2016-08-03 ドクター レディズ ラボラトリーズ リミテッド コレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての置換複素環式アミン化合物
WO2013037396A1 (en) * 2011-09-12 2013-03-21 Bioneer A/S Solution of polymer in api for a solid dosage form
EP2760864B1 (en) 2011-09-27 2018-01-24 Dr. Reddy's Laboratories Ltd. 5-BENZYLAMINOMETHYL-6-AMINOPYRAZOLO[3,4-b]PYRIDINE DERIVATIVES AS CHOLESTERYL ESTER-TRANSFER PROTEIN (CETP) INHIBITORS USEFUL FOR THE TREATMENT OF ATHEROSCLEROSIS
WO2013056108A2 (en) * 2011-10-14 2013-04-18 Array Biopharma Inc. Solid dispersion
RU2672575C2 (ru) * 2012-03-23 2018-11-16 Эррэй Биофарма Инк. Лечение рака головного мозга
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
EP2649989B1 (en) 2012-04-13 2017-10-18 King Saud University Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
JO3339B1 (ar) * 2012-09-11 2019-03-13 Shanghai Inst Pharmaceutical Ind شكل مستقر غير متبلور من الأغوميلاتين وعملية تحضيره والتركيبات الدوائية التي تحتوي عليه
CN104918608A (zh) 2012-11-19 2015-09-16 雷迪博士实验室有限公司 Cetp抑制剂的药物组合物
CA3053189A1 (en) 2012-12-20 2014-06-26 Kashiv Biosciences, Llc Orally disintegrating tablet formulation for enhanced bioavailability
CA2892025C (en) 2013-01-22 2022-02-15 F. Hoffmann-La Roche Ag Solid dispersions comprising 4-{[(2r, 3s, 4r, 5s)-4-(4-chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3- methoxy -benzoic acid and pharmaceutical compositions comprising same with improved bioavailability
TWI615157B (zh) 2013-02-06 2018-02-21 大塚製藥股份有限公司 包括不定形西洛他唑的固體分散劑
WO2015038376A1 (en) * 2013-09-11 2015-03-19 3M Innovative Properties Company Coating compositions, dental structures thereof and methods for generating contrast
WO2015082562A1 (en) * 2013-12-05 2015-06-11 Alrise Biosystems Gmbh Process for the production of drug formulations for oral administration
PT107846B (pt) * 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
BR112017025739A2 (pt) * 2015-05-29 2018-08-07 Sun Pharmaceutical Ind Ltd composição farmacêutica oral de isotretinoína que tem biodisponibilidade aumentada, processo para preparar a mesma e método de tratamento
CA3041155C (en) * 2016-12-13 2021-12-14 Nanjing Transthera Biosciences Co., Ltd. Multi-kinase inhibitor compound, and crystal form and use thereof
SG11201909676WA (en) 2017-04-28 2019-11-28 Seattle Genetics Inc Treatment of her2 positive cancers
KR102082775B1 (ko) * 2017-05-02 2020-02-28 주식회사 삼양바이오팜 수용해도 및 생체이용율이 개선된 조성물
RU2725879C2 (ru) * 2018-07-26 2020-07-07 Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации Интерполимерный носитель для пероральных систем контролируемой доставки активных фармацевтических ингредиентов
US11535600B2 (en) 2018-12-03 2022-12-27 H. Lundbeck A/S Prodrugs of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine
JP7738961B2 (ja) 2020-01-24 2025-09-16 ハンダ セラピューティクス リミテッド ライアビリティ カンパニー ダサチニブの非晶質固体分散体及びその使用
JP2023513045A (ja) 2020-01-31 2023-03-30 ナノコピーア リミテッド ライアビリティ カンパニー 非晶質ニロチニブ微粒子及びその使用
JP7705715B2 (ja) 2020-03-03 2025-07-10 デクセリアルズ株式会社 画像表示装置の製造方法
CA3181361A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
US11980619B2 (en) 2021-07-28 2024-05-14 Nanocopoeia, Llc Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51118816A (en) * 1975-04-08 1976-10-19 Meiji Seika Kaisha Ltd A process for stabilizing non-crystalloidal solid
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
NO864741D0 (no) * 1985-11-27 1986-11-26 Syntex Inc Amorfe, ikke-krystallinske former av terapeutisk virksomme benzimidazolderivater.
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
IL89167A (en) † 1988-02-10 1994-02-27 Hoffmann La Roche Substituted pyrroles, their manufacture and pharmaceutical compositions containing them
JP2528706B2 (ja) † 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
USRE36736E (en) 1989-02-06 2000-06-13 Hoffman-La Roche Inc. Substituted pyrroles
JPH0729926B2 (ja) † 1989-07-25 1995-04-05 大塚製薬株式会社 易吸収性製剤用組成物
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
ATE159426T1 (de) † 1991-04-16 1997-11-15 Nippon Shinyaku Co Ltd Verfahren zur herstellung einer festen dispersion
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
TW493991B (en) 1995-05-08 2002-07-11 Novartis Ag Pharmaceutical composition for oral administration of active agent having low water solubility and process for preparation of the same
GB9511220D0 (en) † 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
ATE240734T1 (de) * 1995-07-26 2003-06-15 Kyowa Hakko Kogyo Kk Zubereitung von xanthinderivaten als feste dispersion
EP0952770A4 (en) † 1995-09-07 1999-12-22 Fuisz Technologies Ltd SYSTEM FOR MAKING SUBSTANTIALLY NON-SOLUBLE BIOALTERANT AGENTS BIOAVAILABLE
DE19548624A1 (de) 1995-12-23 1997-06-26 Boehringer Mannheim Gmbh Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
JPH09208459A (ja) * 1996-02-07 1997-08-12 Eisai Co Ltd 溶解性を改良した製剤
DE69735057T2 (de) 1996-03-12 2006-08-31 PG-TXL Co., L.P., Houston Wasserlösliche paclitaxel-prodrogen
EP0954288B1 (en) * 1996-06-28 2004-08-11 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
PE91598A1 (es) 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
US6229011B1 (en) 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
CN1127500C (zh) 1998-03-17 2003-11-12 弗·哈夫曼-拉罗切有限公司 抑制细胞增殖的取代双吲哚基马来酰亚胺

Also Published As

Publication number Publication date
EP0988863A3 (en) 2000-08-09
DE69916733T2 (de) 2005-03-31
DK0988863T4 (da) 2009-06-08
CN1251312A (zh) 2000-04-26
ATE265232T1 (de) 2004-05-15
KR20000023426A (ko) 2000-04-25
JP2000095708A (ja) 2000-04-04
US6350786B1 (en) 2002-02-26
RS50193B (sr) 2009-05-06
BR9904283A (pt) 2000-09-26
JP2007224048A (ja) 2007-09-06
HK1026632A1 (en) 2000-12-22
NO994583L (no) 2000-03-23
AR022096A1 (es) 2002-09-04
TR199902324A2 (xx) 2000-04-21
AU4880799A (en) 2000-03-23
AU770745B2 (en) 2004-03-04
HU228341B1 (en) 2013-03-28
JP2016196515A (ja) 2016-11-24
SG97131A1 (en) 2003-07-18
MY124377A (en) 2006-06-30
KR100362019B1 (ko) 2002-11-23
CO5140077A1 (es) 2002-03-22
CN1201821C (zh) 2005-05-18
HUP9903189A2 (hu) 2000-06-28
CZ330499A3 (cs) 2000-04-12
NO326928B1 (no) 2009-03-16
HRP990287A2 (en) 2000-06-30
NO994583D0 (no) 1999-09-21
EP0988863A2 (en) 2000-03-29
HRP990287B1 (en) 2004-12-31
RU2240827C2 (ru) 2004-11-27
PE20001049A1 (es) 2000-10-17
HU9903189D0 (en) 1999-11-29
JP6534979B2 (ja) 2019-06-26
TR199902324A3 (tr) 2000-04-21
SI0988863T1 (en) 2004-08-31
DE69916733T3 (de) 2009-09-24
DE69916733D1 (de) 2004-06-03
JP2015187170A (ja) 2015-10-29
SI0988863T2 (sl) 2009-08-31
EP0988863B2 (en) 2009-03-18
JP6253135B2 (ja) 2017-12-27
IL131957A0 (en) 2001-03-19
TWI234465B (en) 2005-06-21
ES2218918T5 (es) 2009-06-23
ES2218918T3 (es) 2004-11-16
DK0988863T3 (da) 2004-08-30
CA2282906A1 (en) 2000-03-22
YU47399A (Direct) 2002-08-12
ID24034A (id) 2000-07-06
PL335592A1 (en) 2000-03-27
IL131957A (en) 2005-06-19
JP2013035875A (ja) 2013-02-21
HUP9903189A3 (en) 2009-07-28
PL202757B1 (pl) 2009-07-31
CZ300215B6 (cs) 2009-03-18
NZ337884A (en) 2001-02-23
CA2282906C (en) 2010-07-20
EP0988863B1 (en) 2004-04-28
PT988863E (pt) 2004-07-30
AR080892A2 (es) 2012-05-16

Similar Documents

Publication Publication Date Title
MA26692A1 (fr) Compositions pharmaceutiques contenant un complexe stable insoluble, procede de preparation et complexe stable insoluble obtenu
KR100622796B1 (ko) 폴리올-ｉｆｎ-베타 공액체
JP5140539B2 (ja) アルブミンを含有していない新規の第ｖｉｉｉ因子処方物
US4409233A (en) Highly concentrated preparations of dopa compounds
FI951266A0 (fi) Pieneliöitä tappavat detergentti-jodi-koostumukset, joilla on alentunut detergenttipitoisuus
EP0971708B1 (en) Nimesulide gel systems for topical use
FR2710840B1 (fr) Compositions viscoélastiques hautement concentrées en composés fluorés, leur préparation et leurs utilisations dans le domaine médical et en cosmétique.
EA002326B1 (ru) Способ солюбилизации фармацевтически активных ингредиентов в воде и в водных носителях
GB2217595A (en) Anti-inflammatory gel
DE68906609D1 (de) Dopamin-vorlaeufer.
EP1056338A1 (en) Gel-type disinfectant having a low alcohol content
HU197208B (en) Process for production of medical compositions containing derivatives of oxicame
US6214866B1 (en) Composition comprising mupirocin and chlorhexidine
JPH05502440A (ja) イブプロフェン摩砕物及びこれを含有する局所用組成物
CA2347170A1 (fr) Laxatif osmotique non fermente pour traiter et prevenir les cancers colorectaux
WO1988003799A1 (en) Pharmaceutical vehicles for reducing transdermal flux
CA2051260A1 (fr) Systeme anti-oxydant a base d'un acide amine basique en association avec au moins un tocopherol ou un de ses derives et au moins un polypeptide non thiole et compositions contenant un tel systeme anti-oxydant
FR2421173A1 (fr) 2-(4-ethylpiperazino)-4-phenylquinoleine et ses sels, utiles notamment comme antidepresseurs, et leur procede de preparation
EP0389079A3 (en) Polyamides bearing functionalized side chains useful as water soluble hypolipidemic agents
JPH08104642A (ja) ヒアルロン酸ナトリウム注射液用安定化組成物
FR3134009B1 (fr) Nécessaire pour le soin des matières kératineuses
MXPA99001136A (en) Composition comprising mupirocin and chlorhexidine
HUP9903088A2 (hu) Mupirocint és klórhexidint tartalmazó gyógyszerkészítmény
ECSP993149A (es) Complejos estables de compuestos escasamente solubles
HK1106705B (en) Novel albumin-free factor viii formulations